ARRY : Summary for Array BioPharma Inc. - Yahoo Finance

U.S. Markets closed

Array BioPharma Inc. (ARRY)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
8.67-0.03 (-0.34%)
At close: 4:00PM EDT
People also watch
EXELARQLCLDXARIARIGL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close8.70
Open8.68
Bid7.95 x 300
Ask9.26 x 300
Day's Range8.50 - 8.80
52 Week Range2.70 - 13.40
Volume1,600,079
Avg. Volume3,885,498
Market Cap1.47B
Beta1.78
PE Ratio (TTM)-13.06
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Shalini Sharp Joins Array BioPharma Board of Directors
    PR Newswire3 days ago

    Shalini Sharp Joins Array BioPharma Board of Directors

    BOULDER, Colo., April 27, 2017 /PRNewswire/ -- Array BioPharma Inc. (ARRY) today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., joined the company's Board of Directors, effective April 27, 2017. Ms. Sharp has served as Chief Financial Officer of Ultragenyx, a biopharmaceutical company focused on rare diseases, since 2012, where she is responsible for leading the corporate finance, strategy, and information technology functions and is a member of the company's executive leadership team. Ms. Sharp brings nearly 20 years of experience in the life sciences industry.

  • TheStreet.com9 days ago

    If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

    Here's how to potentially rake in some fat profits off a number of hot breakout setups.

  • Accesswire13 days ago

    Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen

    NEW YORK, NY / ACCESSWIRE / April 17, 2017 / The Biotech Industry has continued to provide solid gains for investors in 2017, despite all the negative attention the industry has received due to drug pricing ...